靶向CD30的抗体偶联药物Brentuximab vedotin研究进展

Research advances on CD30 targeting antibody drug conjugate Adcetris

Brentuximab vedotin(Adcetris,SGN-35)是由美国西雅图基因公司(Seattle Genetics)和日本武田公司(Takeda)合作开发的一种靶向CD30的新型抗体偶联药物。本品通过布妥昔单抗(Brentuximab)将药物定向富集于肿瘤组织,并通过抗体介导的内吞作用在靶细胞内释放弹头药物彻底杀灭肿瘤,与传统药物相比具有更高的药效和安全性。至今,美国FDA已经获批其用于3种淋巴瘤适应证的治疗;与此同时,其扩大适应证及多种联合给药的相关临床试验结果同样鼓舞人心。笔者对Brentuximab vedotin的基本信息、作用机制、药动学、药效学等进行了概述,并结合其上市后的最新临床研究状况对该类药的研发趋势进行了展望。

Brentuximab vedotin（Adcetris, SGN-35） is a novel CD30 targeting antibody drug conjugates developed by Seattle Genetics and Takeda. Compared with the conventional drugs, Adcetrishasboth higher efficacy and better safety. It has been approved for the treatment of three kinds of lymphomas by U S Food and Drug Administration as yet and the relevant clinical trial data for the expand indications and co-administrations is also encouraging at the same time. Adcetrisenrichesthe antitumor drug in the tumor tissue by the antibody named Brentuximab and releases the final drug after endocytosis to kill the tumor cells completely. We reviewed the basic information, mechanism, pharmacokinetics, pharmacodynamics and clinical trials of Adcetris and prospected its further development trend, which may benefit to the further clinical development of antibody drug conjugates.